Form 4: Myriad Genetics Chief Legal Officer Reports Stock Transactions

Jennifer Lynne Fox, Chief Legal Officer of Myriad Genetics, reports the acquisition of 63,145 shares of common stock and the disposal of 124,916 shares.

Summary

• On March 13, 2025, Jennifer Lynne Fox, the Chief Legal Officer of Myriad Genetics, filed a Form 4.
• The report details changes in her beneficial ownership of Myriad Genetics stock.
• She acquired 63,145 shares of common stock at $0.
• She disposed of 124,916 shares of common stock.
• Following these transactions, she beneficially owns 124,916 shares.
• The acquisition consisted of time-based restricted stock units granted under the company's 2017 equity incentive plan, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document is a standard regulatory filing detailing stock transactions. The impact depends on the investor's interpretation of the insider's actions.

Positives

• The acquisition of restricted stock units indicates a continued alignment of the Chief Legal Officer's interests with the company's long-term performance.

Negatives

• The disposal of 124,916 shares could be perceived negatively, although the reason for the disposal is not specified.

Risks

• Unspecified reasons for the disposal of a significant number of shares could lead to speculation and uncertainty among investors.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may react to the reported stock transactions, potentially influencing the stock price.

Key Dates